文章核心观点 - 公司BDC-1001的免疫刺激抗体偶联物(ISAC)针对人表皮生长因子受体2(HER2)抗原,效果不如公司向投资者表述的那样,很可能无法达到预定的成功标准 [1][5] - 因此,公司夸大了产品管线的临床和商业前景,这是公司维持其业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5] 根据相关目录分别进行总结 公司概况 - 公司名称为Bolt Biotherapeutics, Inc. [1] - 公司股票代码为NASDAQ: BOLT [1] - 公司主要从事免疫刺激抗体偶联物(ISAC)的研发,其中BDC-1001针对HER2抗原 [5] 诉讼情况 - 公司在2021年2月5日至2024年5月14日期间(包括两个日期)的证券交易遭到集体诉讼 [1] - 原告要求在2024年9月3日之前指定首席原告代表集体利益进行诉讼 [1][3] - 原告律师事务所为Rosen Law Firm,声称拥有丰富的证券集体诉讼经验 [4] 指控内容 - 公司对BDC-1001的临床和商业前景做出了虚假或误导性陈述 [5] - 公司夸大了产品管线的前景,这是公司维持业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5]

If you are a shareholder who suffered a loss, click here to participate. LOS ANGELES, July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. CONTACT: The Schall Law Firm Brian Schall, Esq. ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The complaint alleges that on May 14, 2024, Bolt issued a press release announcing that the Company would cease further development of BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer Randall C. Schatzman and Chief Medical Officer Edith Perez would be moved into advisory roles ...

SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt's immune-stimulating antibody conjugate ("ISAC") designed to target a tumor antigen known as human epidermal growth factor receptor 2 ("HER2") that is often found in cance ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bolt To Contact Him Directly To Discuss Their Options Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) On May 14, 2024, Bolt announced in a press release that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)," Bolt's lead asset, "and reduce workforce by approximately 50%." Following Bolt's announcement, multiple analysts d ...

NEW YORK, July 15, 2024 /PRNewswire/ -- What to do next: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigati ...

NEW YORK, July 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SeaStar Medical Holding Corporation (NASDAQ: ICU) and Bolt Biotherapeutics (NASDAQ: BOLT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Class Period: October 31, 2022 - March 26 ...

WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. DETAILS OF THE CASE: According to ...

To be considered for a lead plaintiff role, a Bolt investor must file a motion in the U.S. District Court for the Northern District of California, no later than September 3, 2024. Please contact Edelson Lechtzin LLP to discuss your investment losses, at 844-696-7492 or by e-mail at [email protected]. You can also submit your trading information online HERE. Background on Bolt Biotherapeutics, Inc. focused on developing immunotherapies for cancer treatment, primarily through its "Boltbody" pipeline. The Bolt ...

[Click here for information about joining the class action] Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or c ...